This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Jun;53(6):1121-3; discussion 1123-4.

doi: 10.1016/j.eururo.2008.02.026. Epub 2008 Mar 5.

Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms

François Giuliano

PMID: 18329786
DOI: 10.1016/j.eururo.2008.02.026

Editorial

Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms

François Giuliano. Eur Urol. 2008 Jun.

. 2008 Jun;53(6):1121-3; discussion 1123-4.

doi: 10.1016/j.eururo.2008.02.026. Epub 2008 Mar 5.

Author

François Giuliano

PMID: 18329786
DOI: 10.1016/j.eururo.2008.02.026

No abstract available

PubMed Disclaimer

Comment on

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. Stief CG, et al. Eur Urol. 2008 Jun;53(6):1236-44. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb 4. Eur Urol. 2008. PMID: 18281145 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science